epirubicin (Supratek)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameepirubicin (Supratek)
Drug Alias NameepirubicinSP-1051CSP-1050C
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionDNA intercalators
TargetsDNA
Therapy Area/IndicationsSmall Cell Lung CarcinomaBreast NeoplasmsLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSupratek Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSupratek Pharma
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaBreast NeoplasmsLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksN/A